Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Azacitidine (AZA) and donor lymphocyte infusion (DLI) is a viable salvage approach for chimerism-only relapse following allogeneic blood or marrow transplantation (BMT)

Isabela Stemple, Alex Ambinder, Kathryn Yarkony, Richard Jones, Tania Jain

Blood (2025) 146 (Supplement 1): 7788.

https://doi.org/10.1182/blood-2025-7788

Published: 2025

Journal Articles

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Timothy White, Yun Wang, Cuong Nguyen, Chrystal Louis, Shrikanta Chattopadhyay, Michelle Matzko, Ran Reshef

Blood (2025) 146 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2025-2391

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data

Piyanuch Kongtim, Andrew Portuguese, Soyoung Kim, Andrew Peterson, Hany Elmariah, Lori Muffly, Mark Juckett, Michael Grunwald, Mariam Nawas, Nelli Bejanyan, Tania Jain, Veronika Bachanova, Xia Bi, Ryan Stubbins, Wael Saber, Stefan Ciurea, Bart Scott

Blood (2025) 146 (Supplement 1): 109.

https://doi.org/10.1182/blood-2025-109

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Shirley Mo, Alex Ambinder, Amy DeZern, B. Douglas Smith, Ephraim Fuchs, Gabriel Ghiaur, Gabrielle Prince, Ivana Gojo, Javier Bolanos-Meade, Jonathan Webster, Lukasz Gondek, Richard Jones, Tania Jain, Theodoros Karantanos, William Dalton, Mark Levis

Blood (2025) 146 (Supplement 1): 1710.

https://doi.org/10.1182/blood-2025-1710

Published: 2025

Journal Articles

Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques

John Claiborne, Venkata Preetam Sandeep Kaduluri, Hua-Ling Tsai, Ivana Gojo, Amy DeZern, B. Douglas Smith, Tania Jain, Gabrielle Prince, Javier Bolanos-Meade, Ephraim Fuchs, Gabriel Ghiaur, Lukasz Gondek, William Dalton, Theodoros Karantanos, Ravi Varadhan, Mark Levis, Richard Jones, Jonathan Webster, Alex Ambinder

Blood (2025) 146 (Supplement 1): 44.

https://doi.org/10.1182/blood-2025-44

Published: 2025

Journal Articles

Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-2021

Sachi Singhal, Rahul Mishra, Sankalp Arora, Noha Sharafeldin, Ruchi Desai, Tania Jain, Pankit Vachhani

Blood (2025) 146 (Supplement 1): 2048.

https://doi.org/10.1182/blood-2025-2048

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

Real-world outcomes with blinatumomab as a bridging therapy for allogeneic hematopoietic stem cell transplantation in relapsed/refractory or measurable residual disease-positive B-cell acute lymphoblastic leukemia: A CIBMTR database analysis

Wael Saber, Ruta Brazauskas, Jinalben Patel, Mona Patel, Lori Muffly, Mark Juckett, Michael Grunwald, Nelli Bejanyan, Tania Jain, Veronika Bachanova, Heejoo Jo, Biyao Zou, Jessica Choudhry, Yi Zeng

Blood (2025) 146 (Supplement 1): 6044.

https://doi.org/10.1182/blood-2025-6044

Published: 2025

Journal Articles

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Blood (2025) 146 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2025-2400

Published: 2025

Journal Articles

Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms

Laura Walsh, Venkata Preetam Sandeep Kaduluri, Amy DeZern, Gabrielle Prince, Jonathan Webster, Tania Jain, Theodoros Karantanos, William Dalton, Ivana Gojo, Alex Ambinder, B. Douglas Smith, Lukasz Gondek, Mark Levis, Gabriel Ghiaur

Blood (2025) 146 (Supplement 1): 5227.

https://doi.org/10.1182/blood-2025-5227

Published: 2025

Journal Articles

Donor-derived sars-cov-2-specific T cells to prevent COVID-19 early post allogeneic hematopoietic stem cell transplant

Zara Hasnani, Eamonn Armstrong, Alieya Abbas, Lesley Donoho, Elisabeth Joy, Chase McCann, Abeer Shibli, Rachel DiCioccio, Samantha Murphy, Patrick Hanley, Catherine Bollard, Michael Keller, Tania Jain, Susan Conway

Blood (2025) 146 (Supplement 1): 6028.

https://doi.org/10.1182/blood-2025-6028

Published: 2025

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew T. Kuykendall, Francesca Palandri, John O. Mascarenhas, Haifa Kathrin Al-Ali, Francesco Passamonti, Anna Nekhymchuk, Hilarie Foss, Wayne Rothbaum, Srdan Verstovsek, Florian Heidel

Blood (2024) 144 (Supplement 1): 1808.2.

https://doi.org/10.1182/blood-2024-200966

Published: 2024

Journal Articles

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Blood (2024) 144 (Supplement 1): 4569.1.

https://doi.org/10.1182/blood-2024-194550

Published: 2024

Journal Articles

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

John Preston Claiborne, Daniel Li, B. Douglas Smith, Mark J. Levis, Ivana Gojo, Amy E. DeZern, Alexander J. Ambinder, Tania Jain, Gabrielle T. Prince, Lukasz P. Gondek, Theodoros Karantanos, Gabriel Ghiaur, William Brian Dalton, Jonathan Allen Webster

Blood (2024) 144 (Supplement 1): 5904.

https://doi.org/10.1182/blood-2024-207608

Published: 2024

Journal Articles

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Blood (2024) 144 (Supplement 1): 659.

https://doi.org/10.1182/blood-2024-193678

Published: 2024

Journal Articles

Proteomics Analysis Identifies Candidate Biomarkers for Prediction of Post-CAR-T Cytopenias

Rashmi Madhukar, Christopher Flora, Mary Olesnavich, Erin Sandford, Michelle Rozwadowski, Gen Li, Marcus Johannes Geer, Gregory Yanik, Monalisa Ghosh, David Frame, Jennifer Elise Agrusa, Challice L. Bonifant, Tania Jain, Sung W. Choi, Muneesh Tewari

Blood (2024) 144 (Supplement 1): 7168.

https://doi.org/10.1182/blood-2024-211453

Published: 2024

Journal Articles

High Molecular Risk Mutations (HMR) Drive Progression of CALR -mutated Myeloproliferative Neoplasm (MPN)

Resham Mawalkar, Hua-Ling Tsai, Terra Marie M Jouaneh, Shivam Patel, Christopher Gocke, Eitan Halper-Stromberg, Rena R. Xian, K. C. Rappazzo, Evan M. Braunstein, Alison R. Moliterno, Tania Jain

Blood (2024) 144 (Supplement 1): 3173.

https://doi.org/10.1182/blood-2024-194860

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Azacitidine (AZA) and donor lymphocyte infusion (DLI) is a viable salvage approach for chimerism-only relapse following allogeneic blood or marrow transplantation (BMT)

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques

Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-2021

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Real-world outcomes with blinatumomab as a bridging therapy for allogeneic hematopoietic stem cell transplantation in relapsed/refractory or measurable residual disease-positive B-cell acute lymphoblastic leukemia: A CIBMTR database analysis

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms

Donor-derived sars-cov-2-specific T cells to prevent COVID-19 early post allogeneic hematopoietic stem cell transplant

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Proteomics Analysis Identifies Candidate Biomarkers for Prediction of Post-CAR-T Cytopenias

High Molecular Risk Mutations (HMR) Drive Progression of CALR -mutated Myeloproliferative Neoplasm (MPN)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only